News and features

The ICR and The Royal Marsden welcome the European pharmaceutical regulator’s recommendation that abiraterone acetate, trade name Zytiga™, be approved for use in men with metastatic castration-resistant prostate cancer.

Cancer Research UK has awarded Dr Claus Jorgensen from the ICR a prestigious award as part of a series of grants given to new investigators who are set to become the eminent cancer scientists of the future.

The ICR is leading a project to create the most comprehensive genetic map of prostate cancer yet assembled, which will transform our understanding of the disease and pave the way to better and more targeted treatments. A second project aims to identify genetic faults driving oesophageal cancer.

Scientists from leading London research centres met this week to discuss new ways to help cancer patients by combining their strengths in physics, clinical activities and basic research.

Researchers at the ICR and University of Cambridge led an international study that discovered seven new variants in the human genome that increase the chances of developing prostate cancer.

Scientists have uncovered a new way of killing cancer cells, opening up a potentially highly effective avenue of attack in the fight against all forms of the disease.

An 18 country Europe-wide study has demonstrated the benefit of the new European high dose chemotherapy protocol. The research was led by the ICR, The Royal Marsden and Great Ormond Street Hospital in the UK, and international collaborators.

Accumulating scientific research is increasingly against the theory that mobile phone use causes brain tumours, an expert panel led by the ICR's Professor Tony Swerdlow has found.

A major new clinical trial coordinated by the ICR will determine whether people diagnosed with breast cancer could benefit from receiving fewer radiotherapy treatments than the current UK standard.

Leukaemia “stem cells” can lie dormant in the body for a decade or more after a child achieves remission before being reactivated and causing a relapse, a new study shows.

Cancer drug development could accelerate in the future thanks to a simple and quick blood test that can help reveal the effectiveness of a new treatment, according to research presented this week at the ASCO annual meeting in Chicago.

The Institute of Cancer Research (ICR) was responsible for key research on the BRAF gene, which paved the way for the development of this first-of-its-kind personalised treatment for advanced melanoma.